Lopci, E. http://orcid.org/0000-0001-9732-1094
Aide, N.
Dimitrakopoulou-Strauss, A.
Dercle, L.
Iravani, A.
Seban, R. D.
Sachpekidis, C.
Humbert, O.
Gheysens, O.
Glaudemans, A. W. J. M.
Weber, W. A.
Van den Abbeele, A. D.
Wahl, R. L.
Scott, A. M.
Pandit-Taskar, N.
Hicks, R. J.
Article History
Received: 21 October 2022
Accepted: 12 December 2022
First Online: 20 December 2022
Declarations
:
: Not applicable.
: Not applicable.
: E.L. reports receiving grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) and from the Italian Ministry of Health and faculty remuneration from ESMIT (European School of Multimodality Imaging and Therapy) and MI&T congressi. R. J.H. is on the Scientific Advisory Board of Telix Pharmaceuticals with any honoraria donated to his institution, he is a stock holder in this company, and he is also an honorary Trustee of the International Cancer Imaging Society and honorary Board Member of Neuroendocrine Cancer Australia. W.A.W. has been on the advisory boards and receives compensation from Blue Earth Diagnostics. N.P. declares honoraria from Actinium Pharmaceuticals, AstraZeneca/MedImmune; Consulting or Advisory Role from Illumina, progenics; Speakers’ Bureau from Actinium Pharmaceuticals; Research Funding from Bayer Health; Bristol-Myers Squibb; Clarity Pharmaceuticals; Imaginab; Janssen; Regeneron; Travel, Accommodations Expenses from Bayer. The other authors declare no conflicts of interest.